What is NeuroVision?
Founded in 2010 and headquartered in Sacramento, California, NeuroVision is at the forefront of developing advanced digital imaging and diagnostic technologies. The company's core mission is to identify retinal pathology that is indicative of Alzheimer's disease (AD), aiming to provide early detection and diagnostic solutions for this neurodegenerative condition. This strategic focus places NeuroVision within the rapidly growing intersection of medical technology, diagnostics, and neurodegenerative disease research.
How much funding has NeuroVision raised?
NeuroVision has raised a total of $21.9M across 4 funding rounds:
Series B
$10M
Series C
$11.2M
Debt
$350K
Debt
$350K
Series B (2016): $10M with participation from Wildcat Capital Management
Series C (2018): $11.2M led by Wildcat Capital Management, Nikon-SBI Innovation Fund, and Johnson & Johnson Innovation
Debt (2020): $350K supported by PPP
Debt (2021): $350K featuring PPP
Key Investors in NeuroVision
Wildcat Capital Management
Wildcat Capital Management, founded in 2011 as the single-family office for David Bonderman, specializes in partnership-centric investments in leading companies. The firm employs a collaborative approach, providing management partners with equity capital and strategic support to drive long-term value creation. Wildcat focuses on thematically driven investments across various sectors, including digital customer engagement and automotive services, while maintaining flexibility in investment structure and duration. Their clientele includes founder-owned businesses and strong management teams seeking growth or secondary capital.
Nikon-SBI Innovation Fund
Undisclosed investor participating in the funding round.
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a pharmaceutical manufacturing company founded in 1973 that focuses on positively impacting human health through innovation. The company partners with entrepreneurs and early-stage businesses to develop healthcare solutions that improve lives globally. Johnson & Johnson Innovation operates through a network of regional innovation centers in Boston, California, London, and Shanghai, designed to access the best science and technology in each region. The company provides resources and collaborative approaches across multiple healthcare sectors including consumer products, medical devices, pharmaceuticals, and global public health. Johnson & Johnson Innovation aims to create a leading global innovation network that generates transformational healthcare solutions through strategic partnerships with both B2B and B2C applications.
What's next for NeuroVision?
With a history of significant capital injections, including Series B and Series C funding rounds, NeuroVision appears poised for scaling its operations and advancing its diagnostic solutions. The enterprise-level backing suggests a strong belief in the company's technology and market potential. Future strategic initiatives will likely involve further clinical validation, regulatory approvals, and market penetration to establish its diagnostic tools as a standard in Alzheimer's disease detection. The company's continued pursuit of capital indicates an ongoing commitment to innovation and expansion within the healthcare technology sector.
See full NeuroVision company page
